Azithromycin use in patients with cystic fibrosis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 6, 2015, Pages 1071-1079

  Principi, N ^a   Blasi, F ^a   Esposito, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN;

BRONCHOPNEUMONIA; COMPLICATION; CYSTIC FIBROSIS; HUMAN; PNEUMONIA, BACTERIAL;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHOPNEUMONIA; CYSTIC FIBROSIS; HUMANS; PNEUMONIA, BACTERIAL;

EID: 84939978860     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2347-4     Document Type: Review

References (70)

1. Davies JC, Alton EW, Bush A (2007) Cystic fibrosis. BMJ 335:1255–1259
2. Cystic Fibrosis Foundation. What is the life expectancy for people with CF? Available online at: http://www.cff.org/AboutCF/Faqs/#CF-life-expectancy. Accessed 10 Dec 2014
3. Kumar S, Tana A, Shankar A (2014) Cystic fibrosis—what are the prospects for a cure? Eur J Intern Med 25:803–807
4. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB et al (2013) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187:680–689
5. Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A (2013) Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax 68:1157–1162
6. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L (2009) Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136:1554–1560
7. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I et al (2011) Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 183:635–640
8. Zlosnik JEA, Costa PS, Brant R, Mori PY, Hird TJ, Fraenkel MC et al (2011) Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections. Am J Respir Crit Care Med 183:67–72
9. Foweraker J (2009) Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull 89:93–110
10. Asner S, Waters V, Solomon M, Yau Y, Richardson SE, Grasemann H et al (2012) Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 11:433–439
11. Esposito S, Daccò V, Daleno C, Gambazza S, Montinaro V, Bisogno A et al (2014) Human rhinovirus infection in children with cystic fibrosis. Jpn J Infect Dis 67:399–401
12. Fancello L, Desnues C, Raoult D, Rolain JM (2011) Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. J Antimicrob Chemother 66:2448–2454
13. Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S et al (2012) The airway microbiota in cystic fibrosis: a complex fungal and bacterial community—implications for therapeutic management. PLoS One 7:e36313
14. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET (2012) Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 186:857–865
15. Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M et al (2007) Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 13:1423–1430
16. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP (2010) Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 9:193–198
17. Palm K, Sawicki G, Rosen R (2012) The impact of reflux burden on Pseudomonas positivity in children with cystic fibrosis. Pediatr Pulmonol 47:582–587
18. Kettle AJ, Chan T, Osberg I, Senthilmohan R, Chapman AL, Mocatta TJ et al (2004) Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med 170:1317–1323
19. Starosta V, Griese M (2006) Protein oxidation by chronic pulmonary diseases in children. Pediatr Pulmonol 41:67–73
20. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG (1993) Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985) 75:2419–2424
21. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P et al (2011) Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 184:75–81
22. Watt AP, Courtney J, Moore J, Ennis M, Elborn JS (2005) Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax 60:659–664
23. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075–1082
24. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L et al (2009) Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 180:146–152
25. Brennan S, Sly PD, Gangell CL, Sturges N, Winfield K, Wikstrom M et al (2009) Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. Eur Respir J 34:655–661
26. Sturges NC, Wikström ME, Winfield KR, Gard SE, Brennan S, Sly PD et al (2010) Monocytes from children with clinically stable cystic fibrosis show enhanced expression of Toll-like receptor 4. Pediatr Pulmonol 45:883–889
27. Hubeau C, Le Naour R, Abély M, Hinnrasky J, Guenounou M, Gaillard D et al (2004) Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients. Clin Exp Immunol 135:528–534
28. Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R (2014) Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 143:225–245
29. Imperi F, Leoni L, Visca P (2014) Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front Microbiol 5:178
30. Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno H et al (2005) Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agents Chemother 49:1377–1380
31. Ciofu O, Tolker-Nielsen T, Jensen PO, Wang H, Høiby N (2014) Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev. pii: S0169-409X(14)00282-8
32. Lutz L, Pereira DC, Paiva RM, Zavascki AP, Barth AL (2012) Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol 12:196
33. Tateda K, Ishii Y, Hirakata Y, Matsumoto T, Ohno A, Yamaguchi K (1994) Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity. J Antimicrob Chemother 34:931–942
34. Gillis RJ, Iglewski BH (2004) Azithromycin retards Pseudomonas aeruginosa biofilm formation. J Clin Microbiol 42:5842–5845
35. Sugimura M, Maseda H, Hanaki H, Nakae T (2008) Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:4141–4144
36. Schögler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, Kieninger E et al (2015) Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 45:428–439
37. Halldorsson S, Gudjonsson T, Gottfredsson M, Singh PK, Gudmundsson GH, Baldursson O (2010) Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 42:62–68
38. Imamura Y, Yanagihara K, Mizuta Y, Seki M, Ohno H, Higashiyama Y et al (2004) Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. Antimicrob Agents Chemother 48:3457–3461
39. Gielen V, Johnston SL, Edwards MR (2010) Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 36:646–654
40. Daenas C, Hatziefthimiou AA, Gourgoulianis KI, Molyvdas PA (2006) Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 553:280–287
41. Vanaudenaerde BM, Wuyts WA, Geudens N, Dupont LJ, Schoofs K, Smeets S et al (2007) Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 7:76–82
42. Willems-Widyastuti A, Vanaudenaerde BM, Vos R, Dilisen E, Verleden SE, De Vleeschauwer SI et al (2013) Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor via p38(MAPK) signaling in human airway smooth muscle cells. Cell Biochem Biophys 67:331–339
43. Bosnar M, Kelnerić Z, Munić V, Eraković V, Parnham MJ (2005) Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 49:2372–2377
44. Culić O, Eraković V, Cepelak I, Barisić K, Brajsa K, Ferencić Z et al (2002) Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 450:277–289
45. Marjanović N, Bosnar M, Michielin F, Willé DR, Anić-Milić T, Culić O et al (2011) Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 63:389–397
46. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M et al (2008) Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178:139–148
47. Yamauchi K, Shibata Y, Kimura T, Abe S, Inoue S, Osaka D et al (2009) Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages. Int J Biol Sci 23:667–678
48. Polancec DS, Munic Kos V, Banjanac M, Vrancic M, Cuzic S, Belamaric D et al (2012) Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties. J Leukoc Biol 91:229–243
49. Montenez JP, Van Bambeke F, Piret J, Schanck A, Brasseur R, Tulkens PM et al (1996) Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. Eur J Pharmacol 314:215–227
50. Munić V, Banjanac M, Koštrun S, Nujić K, Bosnar M, Marjanović N et al (2011) Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis. Pharmacol Res 64:298–307
51. Nujić K, Banjanac M, Munić V, Polančec D, Eraković Haber V (2012) Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. Cell Immunol 279:78–86
52. Parnham MJ (2005) Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18:125–131
53. Navarro-Xavier RA, Newson J, Silveira VL, Farrow SN, Gilroy DW, Bystrom J (2010) A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J Immunol 184:1516–1525
54. Southern KW, Barker PM, Solis-Moya A, Patel L (2012) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 11:CD002203
55. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M (2002) Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360:978–984
56. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP (2006) Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61:895–902
57. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA et al (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749–1756
58. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J et al (2010) Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303:1707–1715
59. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57:212–216
60. McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C et al (2007) Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 30:487–495
61. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V et al (2012) Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 142:1259–1266
62. Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH et al (2012) Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 47:641–648
63. Wilms EB, Touw DJ, Heijerman HG, van der Ent CK (2012) Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol 47:658–665
64. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK (2007) Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26:8–12
65. Willekens J, Eyns H, Malfroot A (2015) How long should we maintain long-term azithromycin treatment in cystic fibrosis patients? Pediatr Pulmonol 50:103–104
66. Albert RK, Schuller JL; COPD Clinical Research Network (2014) Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 189:1173–1180
67. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366:1881–1890
68. U.S. Food and Drug Administration (FDA). FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. Available online at: http://www.fda.gov/Drugs/DrugSafety/ucm304372.htm. Accessed 13 Dec 2014
69. Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT et al (2014) Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 11:342–350
70. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S et al (2012) Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 307:2269–2277